CompanyGraph
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 1
- ScaleMarket cap is $1.42B, above the global median of $1.18B
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.76%Below 5Y avg (1.03%)
Annual Rate
CNY 0.60Paid annual
Payout Ratio
41.1%Sustainable
Last Ex-Dividend
Jun 10, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.50BCNY1.42B · vs all stocks (USD)
Trailing P/E
55.72xvs Medical Instruments & Supplies peers
Revenue (TTM)
657.57MCNY98.15M · vs all stocks (USD)
Profit Margin
26.25%vs Medical Instruments & Supplies peers
Beta
0.8110xvs all stocks
52-Week Change
63.73%vs all stocks
Market Capitalization
9.50BCNY1.42B · vs all stocks (USD)
Enterprise Value
9.36BCNY1.40B · vs all stocks (USD)
Trailing P/E
55.72xvs Medical Instruments & Supplies peers
Forward P/E
43.97xvs Medical Instruments & Supplies peers
Price to Sales (TTM)
14.83xvs Medical Instruments & Supplies peers
Price to Book (MRQ)
7.24xvs Medical Instruments & Supplies peers
Enterprise to Revenue
14.24xvs Medical Instruments & Supplies peers
Enterprise to EBITDA
39.18xvs Medical Instruments & Supplies peers
Gross Margin
60.78%vs Medical Instruments & Supplies peers
Profit Margin
26.25%vs Medical Instruments & Supplies peers
Operating Margin
19.90%vs Medical Instruments & Supplies peers
Return on Assets (TTM)
8.06%vs Medical Instruments & Supplies peers
Return on Equity (TTM)
12.88%vs Medical Instruments & Supplies peers
Revenue (TTM)
657.57MCNY98.15M · vs all stocks (USD)
Revenue per Share (TTM)
5.57CNYUpdated Sep 22, 2026Quarterly Revenue Growth
23.10%vs Medical Instruments & Supplies peers
Gross Profit (TTM)
413.23MCNY61.68M · vs all stocks (USD)
EBITDA (TTM)
158.76MCNY23.70M · vs all stocks (USD)
Net Income (TTM)
172.60MCNY25.76M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
4.80%vs Medical Instruments & Supplies peers
Operating Cash Flow (TTM)
151.25MCNY22.58M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
63.92MCNY9.54M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.6000CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
0.76%vs all stocks
5-Year Average Dividend Yield
1.03%vs all stocks
Payout Ratio
41.10%vs Medical Instruments & Supplies peers
Minority Interest (Equity)
-2.23MCNYFY2025 · Dec 31, 2025Revenue
602.61MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
207.01MCNYFY2025 · Dec 31, 2025Gross Profit
395.61MCNYFY2025 · Dec 31, 2025Operating Income
208.02MCNY31.05M · vs all stocks (USD)
Pre-tax Income
190.79MCNYFY2025 · Dec 31, 2025Income Tax Expense
24.88MCNYFY2025 · Dec 31, 2025Net Income
165.91MCNYFY2025 · Dec 31, 2025EBIT
193.78MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
233.59MCNYFY2025 · Dec 31, 2025Research & Development
72.74MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
34.34MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.13MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.80MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.99MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.44CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.44CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
118.57MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
118.57MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
165.91MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.84MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
84.57MCNYFY2025 · Dec 31, 2025Free Cash Flow
57.94MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
587.69MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
165.91MCNYFY2025 · Dec 31, 2025Stock-based Compensation
1.39MCNYFY2025 · Dec 31, 2025Other Non-cash Items
3.97MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-8.68MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-78.01MCNYFY2025 · Dec 31, 2025Capital Expenditures
-26.63MCNYFY2025 · Dec 31, 2025Purchase of Investments
-177.61MCNYFY2025 · Dec 31, 2025Sale of Investments
127.58MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-76.67MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
142.52MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-31.07MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-74.09MCNYFY2025 · Dec 31, 2025Other Financing Charges
-54.43MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-17.07MCNYFY2025 · Dec 31, 2025Shares Outstanding
119.88MSharesUpdated Sep 22, 2026Float Shares
56.04MSharesUpdated Sep 22, 2026% Held by Insiders
41.58%vs all stocks
% Held by Institutions
16.10%vs all stocks
Total Cash (MRQ)
580.95MCNY86.72M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.88CNYUpdated Sep 22, 2026Total Debt (MRQ)
179.52MCNY26.80M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1346xvs Medical Instruments & Supplies peers
Current Ratio (MRQ)
3.88xvs Medical Instruments & Supplies peers
Book Value per Share (MRQ)
11.24CNYUpdated Sep 22, 2026Total Assets
1.63BCNY244.02M · vs all stocks (USD)
Total Current Assets
1.03BCNYFY2025 · Dec 31, 2025Total Liabilities
289.92MCNYFY2025 · Dec 31, 2025Total Non-current Assets
602.42MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
70.54MCNYFY2025 · Dec 31, 2025Total Current Liabilities
219.39MCNYFY2025 · Dec 31, 2025Cash
570.26MCNYFY2025 · Dec 31, 2025Cash Equivalents
17.51MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
587.76MCNYFY2025 · Dec 31, 2025Other Short-term Investments
43.57MCNYFY2025 · Dec 31, 2025Accounts Receivable
106.67MCNYFY2025 · Dec 31, 2025Inventory
260.38MCNYFY2025 · Dec 31, 2025Accounts Payable
79.67MCNYFY2025 · Dec 31, 2025Short-term Debt
84.68MCNYFY2025 · Dec 31, 2025Long-term Debt
58.73MCNYFY2025 · Dec 31, 2025Common Stock (Book)
119.88MCNYFY2025 · Dec 31, 2025Retained Earnings
670.29MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.34BCNY200.74M · vs all stocks (USD)
Treasury Stock
52.58MCNYFY2025 · Dec 31, 202552-Week Low
36.01CNYUpdated Sep 22, 202652-Week High
171.00CNYUpdated Sep 22, 202652-Week Change
63.73%vs all stocks
Beta
0.8110xvs all stocks
50-Day MA
79.95CNYUpdated Sep 22, 2026200-Day MA
76.67CNYUpdated Sep 22, 2026Avg 10-Day Volume
7.04MSharesUpdated Sep 22, 2026Avg 30-Day Volume
9.92MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
1.46CNYUpdated Sep 22, 20266 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Scale
Market cap is $1.42B, above the global median of $1.18BNotable
Market cap (USD): 1,418,639,474.551Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Xinjiang Machinery Research Institute Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Terveystalo Oyj
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Fangda Special Steel Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
PCBL Chemical Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Amara Raja Batteries Limited
Tier 1ProductionThroughput-Bound ConversionFlowRule
Xi'an International Medical Investment Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Privi Speciality Chemicals Limited
Tier 1ProductionThroughput-Bound ConversionFlowRule
Shanghai Zijiang Enterprise Group Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Lingyun Industrial Corporation
Tier 1ProductionThroughput-Bound ConversionFlowRule
The Pennant Group, Inc.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Cheryong Electric Co., Ltd.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Tibet Cheezheng Tibetan Medicine Co. Ltd.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Henan Splendor Science & Technology Co., Ltd.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels